Global Neurointerventional Surgery Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Neurointerventional Surgery Market Size

• The global Neurointerventional Surgery market size was valued at USD 2.8 billion in 2025 and is expected to reach USD 7.1 billion by 2033, at a CAGR of 3% during the forecast period.
• Market growth is primarily driven by rising global incidence of cerebrovascular diseases including ischemic stroke, hemorrhagic stroke, cerebral aneurysms, and arteriovenous malformations (AVMs), increasing adoption of advanced endovascular devices such as flow diverters, mechanical thrombectomy systems, and liquid embolic agents, and growing demand for catheter-based, minimally disruptive neurovascular interventions that offer faster patient recovery and reduced surgical risk compared to open craniotomy approaches.
• Additionally, expanding availability of interventional neurology and neuroradiology capabilities in tertiary care hospitals, growing investments in stroke care infrastructure globally, increasing awareness of the treatment time-window for acute ischemic stroke, and technological advancement in imaging guidance, microcatheters, and neurovascular stenting platforms are supporting strong global market expansion.

Neurointerventional Surgery Market Analysis

• Neurointerventional surgery, encompassing endovascular techniques such as mechanical thrombectomy, coil embolization, flow diversion, carotid artery stenting, and liquid embolic delivery, enables clinicians to treat complex neurovascular conditions through catheter-based access via the femoral or radial artery, eliminating the need for open brain surgery in most cases.
• The growing demand for neurointerventional surgery is driven by surging incidence of stroke and cerebral aneurysm globally, rapid advancement in endovascular neurovascular devices, increasing availability of biplane fluoroscopy suites and cone-beam CT in cath labs, and expanding interventional neuroradiology and neurovascular surgery training programs in academic medical centers worldwide.
• North America dominated the Neurointerventional Surgery market with a share of 38.6% in 2025, supported by a well-developed stroke care ecosystem, high awareness of endovascular stroke treatment protocols, strong reimbursement infrastructure for thrombectomy and aneurysm coiling procedures, and the presence of leading neurovascular device manufacturers such as Medtronic, Stryker Neurovascular, and MicroVention in the United States.
• Asia-Pacific is expected to be the fastest-growing region with a cagr of 11.3%, driven by rapidly rising stroke incidence in aging populations across China, India, Japan, and South Korea, accelerating investments in comprehensive stroke centers, increasing training of interventional neurologists and neuroradiologists, and growing adoption of advanced thrombectomy and aneurysm treatment devices in the region.
• The Neurovascular Stents segment dominated the market with a share of 28.5%, due to its critical role in carotid artery stenting, intracranial atherosclerosis treatment, and aneurysm-associated parent vessel reconstruction, supported by growing clinical volumes and strong evidence base for stent-assisted coiling in complex aneurysm morphologies.

Scope and Neurointerventional Surgery Market Segmentation

Neurointerventional Surgery Market Trends

"Rapid advancement in mechanical thrombectomy technology and expanding stroke intervention windows are reshaping the neurointerventional surgery landscape"

• Growing clinical adoption of next-generation mechanical thrombectomy devices with enhanced aspiration capacity, improved stent retriever design, and distal access catheter systems is significantly improving recanalization rates and functional outcomes in large vessel occlusion (LVO) stroke patients.
• Expansion of the treatment time window for mechanical thrombectomy from 6 to up to 24 hours in select patients based on advanced perfusion imaging is substantially broadening the eligible patient pool and driving procedure volume growth globally.
• Increasing implementation of AI-powered stroke triage and imaging analysis platforms such as Viz.ai and RapidAI is enabling faster patient selection, reducing door-to-puncture times, and facilitating real-time transfer of eligible stroke patients to thrombectomy-capable centers.
• Rising focus on developing combined aspiration-retrieval thrombectomy techniques and next-generation large-bore aspiration catheters is further improving procedural efficiency and first-pass effect (FPE) rates.
• Growing adoption of transradial access for neurointerventional procedures is improving patient comfort, reducing access site complications, and enabling faster post-procedure ambulation.
• Increasing development and regulatory approval of flow diverters with anti-thrombotic surface modifications and enhanced navigability for complex aneurysm morphologies is expanding treatment options for previously uncoilable or surgically high-risk aneurysms.
• Rising investment by leading neurovascular device companies in developing dedicated distal thrombectomy and medium vessel occlusion (MeVO) treatment solutions represents a significant emerging growth area.
• Overall, continued innovation in device design, procedural technique, and digital stroke ecosystem development is transforming neurointerventional surgery into a more precise, time-efficient, and broadly accessible treatment modality.

Neurointerventional Surgery Market Dynamics

Driver

"Surging global burden of cerebrovascular disease and expanding endovascular stroke treatment adoption is driving neurointerventional surgery market growth"

• Rising global prevalence of stroke, cerebral aneurysm, AVM, and carotid artery disease, driven by aging populations, increasing hypertension, diabetes, and lifestyle-related risk factors, is creating sustained and rapidly expanding demand for neurointerventional surgical procedures and associated devices.
• According to the World Stroke Organization, stroke is the second leading cause of death and the third leading cause of disability worldwide, creating an urgent and large-scale clinical need for effective endovascular treatment solutions.
• Growing clinical evidence from landmark trials including DAWN, DEFUSE 3, and HERMES establishing mechanical thrombectomy as the standard of care for LVO stroke is driving rapid global adoption of thrombectomy-capable comprehensive stroke center programs.
• Increasing number of trained interventional neurologists, neuroradiologists, and neurovascular surgeons globally is expanding the physician base for performing complex endovascular procedures.
• Growing government and healthcare system investment in stroke care infrastructure, including establishment of telestroke networks and comprehensive stroke centers, is significantly increasing access to neurointerventional treatment in previously underserved regions.
• Rising patient awareness of stroke warning signs, decreasing onset-to-door times driven by public health campaigns, and improving emergency medical response systems are increasing the proportion of eligible patients reaching thrombectomy-capable centers within the treatment window.
• Expanding reimbursement coverage for mechanical thrombectomy, coil embolization, flow diversion, and carotid stenting procedures in the U.S., Europe, and increasingly in Asia-Pacific is reducing financial barriers and supporting strong procedure volume growth globally.

Restraint / Challenge

"Limited availability of trained neurointerventionalists and inadequate stroke care infrastructure in emerging markets are constraining market penetration"

• The highly specialized nature of neurointerventional procedures demands extensive training in endovascular techniques, neuroimaging interpretation, and periprocedural neurocritical care, resulting in a limited global pool of qualified operators, particularly in lower- and middle-income countries.
• Significant disparities in access to biplane angiography suites, advanced neuroimaging infrastructure, and 24/7 thrombectomy-capable stroke teams between high-income and developing healthcare systems restrict the geographic reach of neurointerventional treatment globally.
• High costs of advanced neurovascular devices including flow diverters, stent retrievers, and aspiration systems, combined with limited or absent reimbursement frameworks in many emerging markets, create substantial access and adoption barriers.
• Risk of procedural complications including vessel perforation, thromboembolic events, contrast nephropathy, and access site bleeding, particularly in anatomically challenging cases, may temper adoption rates and influence device selection.
• Prolonged regulatory approval timelines for novel neurovascular devices in markets such as the EU (MDR framework) and the U.S. (FDA PMA pathway) slow time-to-market for innovative technologies.
• Limited long-term outcome data for newer device platforms such as second-generation flow diverters and novel liquid embolic formulations may create hesitancy among clinicians and payers regarding broad adoption.
• These combined factors collectively create infrastructure, cost, workforce, and regulatory barriers that represent key restraints in the global neurointerventional surgery market.

Neurointerventional Surgery Market Scope

The market is segmented on the basis of product type, indication, end user, and procedure.

By Product Type

On the basis of Product Type, the global Neurointerventional Surgery market is segmented into Neurovascular Stents, Embolic Coils, Flow Diverters, Mechanical Thrombectomy Devices, Liquid Embolic Agents, Microcatheters & Guidewires, Balloon Catheters, and Other Devices.

The Neurovascular Stents segment dominated the market with the largest revenue share of 28.5% in 2025, driven by widespread adoption in carotid artery stenting, intracranial atherosclerosis management, and stent-assisted coiling of wide-neck cerebral aneurysms. Strong clinical evidence supporting stent-assisted neurovascular interventions, combined with growing indications and expanding procedure volumes in both elective and emergent neurovascular settings, are reinforcing segment leadership.

The Flow Diverters segment is expected to witness the fastest growth of 9.8% during the forecast period, fueled by rapid expansion of LVO stroke treatment programs globally, growing adoption of combined aspiration-retrieval techniques, expansion of the thrombectomy treatment time window, and increasing investment by leading manufacturers in next-generation stent retrievers, large-bore aspiration catheters, and distal access systems for medium and distal vessel occlusions.

By Indication

On the basis of Indication, the global Neurointerventional Surgery market is segmented into Ischemic Stroke, Hemorrhagic Stroke & Cerebral Aneurysm, Arteriovenous Malformation (AVM), Carotid Artery Disease, Intracranial Atherosclerosis, and Other Indications.

The Ischemic Stroke segment dominated the market at a share of 42.3% in 2025, driven by the high global prevalence of intracranial aneurysms, strong clinical adoption of endovascular coil embolization and flow diversion as first-line treatment approaches for ruptured and unruptured aneurysms, and robust evidence supporting endovascular techniques over open surgical clipping in most aneurysm morphologies.

The Intracranial Atherosclerosis segment is expected to witness the fastest growth rate of 10.2% during the forecast period, fueled by rapidly expanding mechanical thrombectomy adoption, growing awareness of LVO stroke recognition and transfer protocols, increasing stroke center accreditation globally, and continuous device innovation targeting improved recanalization rates and functional independence outcomes in stroke patients.

By End User

On the basis of End User, the global Neurointerventional Surgery market is segmented into Hospitals & Comprehensive Stroke Centers, Ambulatory Surgical Centers (ASCs), Specialty Neurovascular Clinics, and Academic & Research Institutes.

The Hospitals & Comprehensive Stroke Centers segment dominated the market with a share of 61.4% in 2025, driven by the high complexity and acuity of neurointerventional procedures requiring 24/7 neuroimaging, angiography suites, neurocritical care, and multidisciplinary neurovascular teams available exclusively in hospital and comprehensive stroke center settings.

The Ambulatory Surgical Centers (ASCs) segment is expected to witness the fastest growth rate of 11.5% during the forecast period, driven by the increasing feasibility of performing elective neurointerventional procedures such as unruptured aneurysm coiling and carotid stenting in ambulatory settings, growing payer support for lower-cost ASC-based neurovascular interventions, and expansion of high-capability hybrid procedure rooms in ASCs.

By Procedure

On the basis of Procedure, the global Neurointerventional Surgery market is segmented into Mechanical Thrombectomy, Coil Embolization, Flow Diversion, Carotid Artery Stenting, Balloon Angioplasty, and Liquid Embolic Delivery.

The Mechanical Thrombectomy segment dominated the market with a share of 35.7% in 2025, driven by decades of clinical evidence, widespread procedural familiarity, and established use as the primary endovascular treatment approach for both ruptured and unruptured cerebral aneurysms across interventional neuroradiology centers globally. Its broad applicability across aneurysm sizes, locations, and patient profiles supports consistent procedure volumes worldwide.

The Flow Diversion segment is expected to witness the fastest growth of 10.6% during the forecast period, fueled by rapid global expansion of LVO stroke treatment capabilities, continuous improvement in thrombectomy device design and technique, increasing stroke awareness driving earlier hospital presentation, and expanding insurance and government reimbursement coverage for thrombectomy procedures across North America, Europe, and Asia-Pacific.

Neurointerventional Surgery Market Regional Analysis

• North America dominated the Neurointerventional Surgery market with the largest revenue share in 2025, supported by an extensive network of Joint Commission-certified Comprehensive Stroke Centers (CSCs) and Thrombectomy-capable Stroke Centers (TSCs), strong reimbursement infrastructure for endovascular procedures, high awareness among emergency physicians of LVO stroke identification and inter-hospital transfer protocols, and the presence of leading neurovascular device innovators such as Medtronic, Stryker Neurovascular, Penumbra, and MicroVention in the United States.
• Healthcare systems across the region place strong emphasis on evidence-based, time-sensitive stroke care delivery, driving widespread adoption of mechanical thrombectomy, coil embolization, flow diversion, and carotid stenting as standard neurovascular treatment protocols. Rising procedure volumes for both emergent stroke interventions and elective aneurysm management are further strengthening market leadership.
• This dominant position is further supported by robust clinical trial infrastructure generating ongoing evidence for novel devices and techniques, strong investment in neurointerventional training fellowships, and continued expansion of telestroke and hub-and-spoke stroke referral networks that maximize patient access to thrombectomy-capable centers across North America.

U.S. Neurointerventional Surgery Market Insight

The U.S. Neurointerventional Surgery market holds a dominant position globally, driven by the highest concentration of accredited comprehensive stroke centers, robust Medicare and Medicaid reimbursement for mechanical thrombectomy and aneurysm coiling, and strong adoption of advanced neurovascular devices. The U.S. also leads in clinical trial activity for novel neurointerventional technologies and benefits from a highly trained interventional neurology and neuroradiology physician workforce, strong commercial infrastructure for rapid device adoption, and growing ASC-based elective neurovascular program development.

Europe Neurointerventional Surgery Market Insight

The Europe Neurointerventional Surgery market is witnessing steady growth, driven by strong demand across Germany, France, the U.K., and the Netherlands, where well-funded national health systems are increasingly supporting stroke intervention programs and aneurysm treatment capabilities. Growing adoption of mechanical thrombectomy following clinical evidence from HERMES and subsequent European trials, increasing EU-level funding for stroke care improvement initiatives, and rising adoption of flow diversion for complex aneurysms are supporting market expansion across the region.

U.K. Neurointerventional Surgery Market Insight

The U.K. Neurointerventional Surgery market is experiencing steady growth, driven by NHS England's ongoing expansion of thrombectomy services across regional stroke networks and increasing investment in neurointerventional suite infrastructure at major neuroscience centers. Growing clinical adoption of coil embolization and flow diversion for aneurysm management, rising emphasis on reducing stroke-related disability burden, and expanding interventional neuroradiology training programs are further supporting market development across the country.

Germany Neurointerventional Surgery Market Insight

The Germany Neurointerventional Surgery market is expected to grow steadily during the forecast period, driven by a high density of neuroradiology and neurovascular surgery expertise, strong hospital infrastructure for advanced stroke care, and increasing procedural volumes for both emergent thrombectomy and elective aneurysm treatment. Germany's advanced biomedical engineering ecosystem and strong clinical research activity in neurovascular intervention are further supporting adoption of next-generation endovascular neurovascular devices and techniques.

Japan Neurointerventional Surgery Market Insight

The Japan Neurointerventional Surgery market is witnessing steady growth, driven by Japan's aging population with high cerebrovascular disease prevalence, strong government support for advanced stroke care, and well-established neurointerventional infrastructure at leading university hospitals. Japan's early regulatory pathway for novel neurovascular devices, combined with its strong culture of procedural precision and technology adoption among interventional neuroradiologists, supports continued growth in thrombectomy, aneurysm coiling, and flow diversion procedure volumes.

India Neurointerventional Surgery Market Insight

The India Neurointerventional Surgery market is experiencing strong growth, driven by rapidly rising stroke and cerebrovascular disease burden, increasing number of trained interventional neurologists and neuroradiologists, expanding private hospital investment in biplane angiography and hybrid cath labs, and growing awareness of stroke treatment time-sensitivity among emergency physicians and the public. Government initiatives to establish stroke care networks, increasing medical tourism for complex neurovascular procedures, and rising adoption of endovascular treatment across metro and tier-2 cities are further strengthening market expansion across the country.

Neurointerventional Surgery Market Share

The Neurointerventional Surgery industry is primarily led by well-established companies, including:

• Medtronic plc (Ireland)
• Stryker Neurovascular (U.S.)
• MicroVention Inc. – Terumo Corporation (U.S./Japan)
• Johnson & Johnson MedTech – Cerenovus (U.S.)
• Penumbra Inc. (U.S.)
• Balt Group (France)
• phenox GmbH (Germany)
• Acandis GmbH (Germany)
• Rapid Medical (Israel)
• Imperative Care (U.S.)
• Q'Apel Medical (U.S.)
• Perflow Medical (Israel)

Latest Developments in Global Neurointerventional Surgery Market

• In July 2025, Johnson & Johnson MedTech highlighted new neurovascular innovations and clinical data at the Society of NeuroInterventional Surgery (SNIS) 2025 meeting, reinforcing its long-term R&D commitment and showcasing advancements in embolization and neurovascular treatment technologies.
• In April 2025, CereVasc, Inc. received U.S. FDA Breakthrough Device Designation for its eShunt System, designed for treating communicating hydrocephalus. This designation accelerates regulatory review and reflects growing innovation in minimally invasive neurointerventional solutions.
• In June 2025, Penumbra, Inc. received FDA clearance for its Ruby XL embolization system, designed for large vessel embolization procedures, improving procedural efficiency and reducing radiation exposure in neurovascular interventions.
• In April 2026, Terumo Corporation (Terumo Neuro) received U.S. FDA approval for a dual-layer carotid stent system, marking a significant advancement in stroke prevention and carotid artery disease treatment.
• In May 2026, GE HealthCare launched CleaRecon DL, an AI-powered imaging solution that enhances cone-beam CT imaging for neurointerventional procedures, improving visualization and procedural accuracy.

SKU-75881